242 related articles for article (PubMed ID: 37725704)
1. The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
Lawson M; Cureton N; Ros S; Cheraghchi-Bashi A; Urosevic J; D'Arcy S; Delpuech O; DuPont M; Fisher DI; Gangl ET; Lewis H; Trueman D; Wali N; Williamson SC; Moss J; Montaudon E; Derrien H; Marangoni E; Miragaia RJ; Gagrica S; Morentin-Gutierrez P; Moss TA; Maglennon G; Sutton D; Polanski R; Rosen A; Cairns J; Zhang P; Sánchez-Guixé M; Serra V; Critchlow SE; Scott JS; Lindemann JPO; Barry ST; Klinowska T; Morrow CJ; Carnevalli LS
Cancer Res; 2023 Dec; 83(23):3989-4004. PubMed ID: 37725704
[TBL] [Abstract][Full Text] [Related]
2. Design of SERENA-6, a phase III switching trial of camizestrant in
Turner N; Huang-Bartlett C; Kalinsky K; Cristofanilli M; Bianchini G; Chia S; Iwata H; Janni W; Ma CX; Mayer EL; Park YH; Fox S; Liu X; McClain S; Bidard FC
Future Oncol; 2023 Mar; 19(8):559-573. PubMed ID: 37070653
[TBL] [Abstract][Full Text] [Related]
3. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
4. Decreased ER dependency after acquired resistance to CDK4/6 inhibitors.
Iida M; Toyosawa D; Nakamura M; Tsuboi K; Tokuda E; Niwa T; Ishida T; Hayashi SI
Breast Cancer; 2020 Sep; 27(5):963-972. PubMed ID: 32297248
[TBL] [Abstract][Full Text] [Related]
5. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
Sammons S; Shastry M; Dent S; Anders C; Hamilton E
Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
[TBL] [Abstract][Full Text] [Related]
6. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ
Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346
[TBL] [Abstract][Full Text] [Related]
7. A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.
Hamilton E; Oliveira M; Turner N; García-Corbacho J; Hernando C; Ciruelos EM; Kabos P; Borrego MR; Armstrong A; Patel MR; Vaklavas C; Twelves C; Boni V; Incorvati J; Brier T; Gibbons L; Klinowska T; Lindemann JPO; Morrow CJ; Sykes A; Baird RD
Ann Oncol; 2024 May; ():. PubMed ID: 38729567
[TBL] [Abstract][Full Text] [Related]
8. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
Ladd B; Mazzola AM; Bihani T; Lai Z; Bradford J; Collins M; Barry E; Goeppert AU; Weir HM; Hearne K; Renshaw JG; Mohseni M; Hurt E; Jalla S; Bao H; Hollingsworth R; Reimer C; Zinda M; Fawell S; D'Cruz CM
Oncotarget; 2016 Aug; 7(34):54120-54136. PubMed ID: 27472462
[TBL] [Abstract][Full Text] [Related]
9. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
[TBL] [Abstract][Full Text] [Related]
10. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E
Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886
[TBL] [Abstract][Full Text] [Related]
11. Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
Alves CL; Ehmsen S; Terp MG; Portman N; Tuttolomondo M; Gammelgaard OL; Hundebøl MF; Kaminska K; Johansen LE; Bak M; Honeth G; Bosch A; Lim E; Ditzel HJ
Nat Commun; 2021 Aug; 12(1):5112. PubMed ID: 34433817
[TBL] [Abstract][Full Text] [Related]
12. Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers.
Soosainathan A; Iravani M; El-Botty R; Alexander J; Sourd L; Morisset L; Painsec P; Orha R; Nikitorowicz-Buniak J; Pancholi S; Haider S; Dowsett M; Marangoni E; Martin LA; Isacke CM
Cancer Res; 2024 Jan; 84(1):17-25. PubMed ID: 37801608
[TBL] [Abstract][Full Text] [Related]
13. Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer.
Guarducci C; Nardone A; Russo D; Nagy Z; Heraud C; Grinshpun A; Zhang Q; Freelander A; Leventhal MJ; Feit A; Cohen Feit G; Feiglin A; Liu W; Hermida-Prado F; Kesten N; Ma W; De Angelis C; Morlando A; O'Donnell M; Naumenko S; Huang S; Nguyen QD; Huang Y; Malorni L; Bergholz JS; Zhao JJ; Fraenkel E; Lim E; Schiff R; Shapiro GI; Jeselsohn R
Clin Cancer Res; 2024 May; 30(9):1889-1905. PubMed ID: 38381406
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
15. CDK4/6 Inhibitor Efficacy in
Lloyd MR; Brett JO; Carmeli A; Weipert CM; Zhang N; Yu J; Bucheit L; Medford AJ; Wagle N; Bardia A; Wander SA
NEJM Evid; 2024 May; 3(5):EVIDoa2300231. PubMed ID: 38815172
[TBL] [Abstract][Full Text] [Related]
16. Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
Whittle JR; Vaillant F; Surgenor E; Policheni AN; Giner G; Capaldo BD; Chen HR; Liu HK; Dekkers JF; Sachs N; Clevers H; Fellowes A; Green T; Xu H; Fox SB; Herold MJ; Smyth GK; Gray DHD; Visvader JE; Lindeman GJ
Clin Cancer Res; 2020 Aug; 26(15):4120-4134. PubMed ID: 32245900
[TBL] [Abstract][Full Text] [Related]
17. EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
Belli S; Esposito D; Ascione CM; Messina F; Napolitano F; Servetto A; De Angelis C; Bianco R; Formisano L
Cancer Lett; 2024 Jul; 593():216968. PubMed ID: 38788968
[TBL] [Abstract][Full Text] [Related]
18. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
19. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.
Choong GM; Liddell S; Ferre RAL; O'Sullivan CC; Ruddy KJ; Haddad TC; Hobday TJ; Peethambaram PP; Liu MC; Goetz MP; Giridhar KV
Breast Cancer Res Treat; 2022 Nov; 196(1):229-237. PubMed ID: 36045271
[TBL] [Abstract][Full Text] [Related]
20. Oral estrogen receptor PROTAC® vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models.
Gough SM; Flanagan JJ; Teh J; Andreoli M; Rousseau E; Pannone M; Bookbinder M; Willard R; Davenport K; Bortolon E; Cadelina G; Gordon D; Pizzano J; Macaluso J; Soto L; Corradi J; Digianantonio K; Drulyte I; Morgan A; Quinn C; Békés M; Ferraro C; Chen X; Wang G; Dong H; Wang J; Langley DR; Houston J; Gedrich R; Taylor IC
Clin Cancer Res; 2024 May; ():. PubMed ID: 38819400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]